Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Radiother Oncol. 2018 Jun 28;128(3):442–451. doi: 10.1016/j.radonc.2018.06.013

Table 1.

Patient and tumor characteristics.

Moderate/Severe Univariate
All Patients
N=97 (%)
No/Mild Dysphagia
(DIGEST* <2)
N=67 (%)
Dysphagia
(DIGEST ≥2)
N=30 (%)
Analysis
P-value

Age, median 61 60 62 0.296
(range), (95% CI) (35–86),(59-62) (35–82),(58–62) (40–86),(59–66)
Sex 0.142
Male 88(91) 59(67) 29(33)
Female 9(9) 8(89) 1(11)
Subsite 0.667
Base of Tongue 45(46) 30(67) 15(33)
Tonsil 38(39) 27(71) 11(29)
Others 14(15) 10(71) 4(29)
T Stage*** <0.0001**
0 7(7) 7(100) 0
1 31(32) 27(87) 4(13)
2 32(33) 22(69) 10(31)
3 13(13) 8(61) 5(39)
4 14(14) 3(21) 11(79)
N Stage*** 0.286
x-1 19(20) 15(79) 4(21)
2–3 78(80) 52(67) 26(33)
Treatment Modalities 0.0006**
Radiotherapy alone 16 (16) 14(87) 2(13)
CCRT Only 57(59) 44(77) 13(23)
Combined
IC+CCRT
23(23) 9(39) 14(61)
Radiotherapy 0.542
Definitive 88(91) 60(68) 28(32)
Post-op 9(9) 7(78) 2(22)
Smoking Status 0.163
Former Smoker 40(41) 31(77) 9(23)
Current Smoker 6(6) 5(83) 1(17)
Never Smoker 51(53) 31(60) 20(40)
HPV/P16 Status 0.935
Positive 90(93) 62(69) 28(31)
Negative 3(3) 2(67) 1(33)
Unknown 4(4) 3(75) 1(25)
Baseline Dysphagia Grade (per DIGEST) 0.033**
0 65(67) 50(77) 15(23)
1 25(26) 14(56) 11(44)
2 5(5) 3(60) 2(40)
3 2(2) 0 2(100)
Total RT Dose
(Gy)
70(70–50) 68(67–69) 69(68–70) 0.041**
*

DIGEST per 3–6 months post-RT modified barium swallowing study

**

Statistically significant P-value < 0.05

***

TNM classification per AJCC staging 7th edition

Abbreviations: DIGEST; Dynamic Imaging Grade of Swallowing Toxicity, CCRT; concurrent chemo/radiotherapy, IC; induction chemotherapy, RT; radiotherapy.